Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 10, 2004, Pages 567-573

  Yasumatsu, Ryuji ^a   Nakashima, Torahiko ^a   Masuda, Muneyuki ^a   Ito, Aya ^a   Kuratomi, Yuichiro ^a   Nakagawa, Takashi ^a   Komune, Shizuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

ACE inhibitor; Angiotensin II; Head and neck squamous cell carcinoma; Perindopril; VEGF

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LUCIFERASE; MESSENGER RNA; PERINDOPRIL; PERINDOPRILAT; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SQUAMOUS CELL CARCINOMA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CELL LINE, TUMOR; FEMALE; HEAD AND NECK NEOPLASMS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PERINDOPRIL; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 5644304562     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0582-7     Document Type: Article

References (30)

1. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761
2. Burris JF (1995) The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol 35:337-342
3. Chen L, Re RN, Prakash O, Mondal D (1991) Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 196:280-283
4. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM (1991) Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450-456
5. Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF (1997) Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 77:659-664
6. Fernandez LA, Twickler J, Mead A (1985) Neovascularization produced by angiotensin II. J Lab Clin Med 105:141-145
7. Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359-1364
8. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
9. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931-10934
10. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441-447
11. Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273:1450-1456
12. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, Addeo R, Makuuchi M, Esumi H (2000) Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 95:189-197
13. Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE (1998) Clinical research on antiangiogenic therapy. Pharmacol Res 37:1-16
14. Lau K, Bicknell R (1999) Antiangiogenic gene therapy. Gene Ther 6:1793-1795
15. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179-184
16. Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, Komiyama S, Weinstein IB (2002). The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 93:329-339
17. Matsumoto G, Ohmi Y, Shindo J (2001) Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo. Oral Oncol 37:369-378
18. Minchenko A, Salceda S, Bauer T, Caro J (1994) Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40:35-39
19. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E (1997) Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 33:369-374
20. Mustonen T, Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129:895-898
21. Noguchi R, Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Mitoro A, Tsujinoue H, Imazu H, Masaki T, Fukui H (2003) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9:6038-6045
22. Page EL, Robitaille GA, Pouyssegur J, Richard DE (2002) Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 277:48403-48409
23. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81:761-766
24. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674
25. Shemirani B, Crowe DL (2000) Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol 36:61-66
26. Shemirani B, Crowe DL (2002) Hypoxic induction of HIF-1alpha and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol 38:251-257
27. Shpitzer T, Chaimoff M, Gal R, Stern Y, Feinmesser R, Segal K (1996) Tumor angiogenesis as a prognostic factor in early oral tongue cancer. Arch Otolaryngol Head Neck Surg 122:865-868
28. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671-679
29. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7:1073-1078
30. Yoshiji H, Kuriyama S, Fukui H (2002) Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23:348-356